From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 |  | All (N=364) |
---|---|---|
Gender | Female | 232 (64%) |
Male | 131 (36%) | |
Unknown | 1 (<1%) | |
Age, years | Median (IQR) | 14 (10, 17) |
Top Rheumatology Diagnoses | Juvenile Idiopathic Arthritis (JIA) | 244 (67%) |
Polyarthritis | 124 (34%) | |
Oligoarthritis | 65 (18%) | |
Systemic | 23 (6%) | |
Psoriatic | 6 (2%) | |
Enthesitis | 26 (7%) | |
Autoinflammatory | 51 (14%) | |
Connective Tissue Disorder | 42 (12%) | |
Other | 27 (7%) | |
Comorbidities (25 missing) | None stated | 282 (77%) |
Obesity | 15 (4%) | |
Ocular inflammation | 28 (8%) | |
Asthma | 7 (2%) | |
Required Hospitalisation | Yes | 20 (5%) |
No | 271 (74%) | |
Missing | 73 (20%) | |
Top Symptoms Reported | Fever | 146 (40%) |
Cough | 109 (30%) | |
Headache | 75 (21%) | |
Rhinorrhea | 75 (21%) | |
Deaths due to COVID-19 | Yes | 1 (<1%) |
Treatment at onset of COVID-19 infection | Glucocorticoids | 42 (12%) |
csDMARDs | 161 (44%) | |
Methotrexate | 125 (34%) | |
Antimalarials | 22 (6%) | |
Mycophenolate | 17 (5%) | |
b/tsDMARDs | 161 (44%) | |
Anti-TNF | 119 (33%) | |
IL-6 | 21 (6%) | |
IL-1 | 12 (3%) | |
JAK | 2 (<1%) | |
Any DMARD | 251 (69%) | |
Disease Activity | Remission | 146 (40%) |
Low | 103 (28%) | |
Moderate / High | 31 (9%) | |
Unknown | 84 (23%) |